Skip to main content

Advertisement

Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: Melatonin synergizes BRAF-targeting agent vemurafenib in melanoma treatment by inhibiting iNOS/hTERT signaling and cancer-stem cell traits

Fig. 1

Melatonin enhanced the inhibition of cell proliferation by vemurafenib. (a). Human melanoma cells were treated with the increasing doses of vemurafenib (VE), melatonin (MT) alone or combined for 48 h, and the cell viability was examined by MTT assay. (b). The IC50 values of vemurafenib (VE) for cell viability inhibition in cells treated with or without melatonin (MT) were determined. (c). Clone formation in A375 cells and SK-mel-28 cells treated with vemurafenib (VE) (2.5 μM) and melatonin (MT) (1.0 mM) for 48 h were observed and the colony number were quantified. (d). AKT signaling-associated protein markers: PDK1, p-PTEN, p-AKT and AKT was respectively detected by Western blot assay in melanoma cells with indicated treatment. (e). DNA content-based cell cycle analysis was carried out in melanoma cells treated with VE or MT alone or their combination for 48 h. The percentage of cells at each phase of cell cycle was quantified. (f). G1/S checkpoint pathway was detected by Western blot assay in melanoma cells with indicated treatment. The data is presented as mean ± SD of three separate experiments, *P < 0.05, **P < 0.01, significant differences compared to the control groups

Back to article page